|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM143075012 |
| 003 |
DE-627 |
| 005 |
20231223030010.0 |
| 007 |
tu |
| 008 |
231223s2003 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0477.xml
|
| 035 |
|
|
|a (DE-627)NLM143075012
|
| 035 |
|
|
|a (NLM)14585278
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Richardson, Bruce
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a DNA methylation and autoimmune disease
|
| 264 |
|
1 |
|c 2003
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 02.12.2003
|
| 500 |
|
|
|a Date Revised 08.11.2019
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a DNA methylation plays an essential role in maintaining T-cell function. A growing body of literature indicates that failure to maintain DNA methylation levels and patterns in mature T cells can result in T-cell autoreactivity in vitro and autoimmunity in vivo. Defective maintenance of DNA methylation may be caused by drugs such as procainamide or hydralazine, or failure to activate the genes encoding maintenance DNA methyltransferases during mitosis, resulting in the development of a lupus-like disease or perhaps other autoimmune disorders. This paper reviews the evidence supporting a role for abnormal T-cell DNA methylation in causing autoimmunity in an animal model of drug-induced lupus, and discusses some of the mechanisms involved. T cells from patients with active lupus have evidence for most if not all of the same methylation abnormalities, suggesting that abnormal DNA methylation plays a role in idiopathic human lupus as well
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, U.S. Gov't, P.H.S.
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
7 |
|a Hydralazine
|2 NLM
|
| 650 |
|
7 |
|a 26NAK24LS8
|2 NLM
|
| 650 |
|
7 |
|a Procainamide
|2 NLM
|
| 650 |
|
7 |
|a L39WTC366D
|2 NLM
|
| 650 |
|
7 |
|a Azacitidine
|2 NLM
|
| 650 |
|
7 |
|a M801H13NRU
|2 NLM
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 109(2003), 1 vom: 30. Okt., Seite 72-9
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:109
|g year:2003
|g number:1
|g day:30
|g month:10
|g pages:72-9
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 109
|j 2003
|e 1
|b 30
|c 10
|h 72-9
|